https://www.oncologynurseadvisor.com Thu, 29 Feb 2024 14:31:27 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/gynecologic-cancer/pembrolizumab-plus-chemotherapy-under-review-for-primary-advanced-or-recurrent-endometrial-cancer/ Thu, 29 Feb 2024 14:15:00 +0000 https://www.oncologynurseadvisor.com/?p=116846 https://www.oncologynurseadvisor.com/home/cancer-types/melanoma/one-time-cell-therapy-amtagvi-gets-accelerated-approval-for-advanced-melanoma-2/ Mon, 26 Feb 2024 14:05:00 +0000 https://www.oncologynurseadvisor.com/?p=116801 Amtagvi is a tumor-derived autologous T cell immunotherapy designed to deploy patient-specific T cells called TIL cells to locate and attack cancer cells.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/perioperative-nivolumab-based-regimen-under-review-for-resectable-nsclc/ Tue, 20 Feb 2024 14:15:00 +0000 https://www.oncologynurseadvisor.com/?p=116578 https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/trastuzumab-deruxtecan-gets-priority-review-for-metastatic-her2-solid-tumors-2/ Fri, 02 Feb 2024 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=116282 https://www.oncologynurseadvisor.com/home/cancer-types/head-and-neck-cancer/nasopharyngeal-carcinoma-treatment-loqtorzi-now-available/ Fri, 05 Jan 2024 15:40:00 +0000 https://www.empr.com/?p=213346 https://www.oncologynurseadvisor.com/home/cancer-types/genitourinary-cancer/pembrolizumab-plus-enfortumab-vedotin-under-review-for-first-line-tx-of-urothelial-cancer/ Thu, 07 Dec 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=114573 The sBLA is supported by data from the phase 3 KEYNOTE-A39 trial, which compared pembrolizumab plus enfortumab vedotin-ejfv to standard of care chemotherapy.]]> https://www.oncologynurseadvisor.com/home/cancer-types/brain-cancer/tovorafenib-under-review-for-relapsed-or-progressive-pediatric-low-grade-glioma/ Thu, 09 Nov 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=113840 Tovorafenib is an oral, brain-penetrant, highly-selective type II RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/fda-approves-keytruda-neoadjuvant-adjuvant-treatment-resectable-nsclc/ Wed, 25 Oct 2023 14:30:00 +0000 https://www.empr.com/?p=208514 The approval was based on data from the phase 3 KEYNOTE-671 trial.]]> https://www.oncologynurseadvisor.com/home/cancer-types/melanoma/fda-approves-opdivo-for-completely-resected-stage-iib-c-melanoma-2/ Wed, 25 Oct 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=113412 Opdivo is a programmed death receptor-1 (PD-1) blocking antibody. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/aphexda-approved-for-stem-cell-mobilization-for-asct-in-multiple-myeloma/ Tue, 19 Sep 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=110486 Aphexda is expected to be available in September 2023. ]]>